| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹28.12 Cr |
| Reserved for Market Maker | ₹1.41 Cr |
| Net Issue Size | ₹28.12 Cr |
| Fresh Issue | ₹26.71 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹80.00-85.00 per share |
| NSE Code | INVICTA |
| Registrar | Bigshare Services Pvt.Ltd. |
| Lead Managers | Socradamus Capital Pvt.Ltd. |
| Allotment Status | |
| DRHP |
| RHP |
| Final Prospectus |
| Anchor List |
![]() ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
![]() ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 3,200 shares · Multiples of 1,600 shares
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions. The company provides pathology and radiology testing, including imaging, radiology, and teleradiology, under the brand 'PC Diagnostics' through 7 diagnostic centres and a central laboratory across Mumbai, Maharashtra.
Invicta Diagnostics Limited (trading as PC Diagnostics) is a Mumbai-based diagnostic services company specialising in integrated pathology and radiology solutions. The company follows a hub‑and‑spoke model across the Mumbai Metropolitan Region, featuring:
The company offers around 60 routine and 487 specialised pathology tests, plus about 96 basic and 130 advanced radiology tests.
Invicta Diagnostics provides a comprehensive suite of diagnostic services, which includes:
As of October 31, 2025, the company employed 157 permanent employees.
Competitive Strength:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra | 21.11 |
| 2 | General Corporate Purposes | 4.07 |
| 3 | Issue Expenses | 2.94 |
| Total | 28.12 |
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 34.90 | 21.22 | 15.89 |
| Total Income | 17.08 | 30.18 | 15.90 |
| Profit After Tax | 4.08 | 4.93 | 3.81 |
| EBITDA | 6.77 | 9.20 | 7.09 |
| NET Worth | 23.68 | 13.60 | 8.67 |
| Reserves and Surplus | 14.42 | 5.18 | 8.54 |
| Total Borrowing | 3.72 | 3.54 | 3.81 |
| Amount in ₹ Crore | |||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 44.28% |
| ROCE | 42.00% |
| Debt / Equity | 0.26% |
| RoNW | 36.25% |
| PAT Margin | 16.38% |
| EBITDA Margin | 30.57% |
| Price to Book Value | 5.26 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 5.86 | 6.50 |
| P/E (x) | 14.51 | 13.08 |
| Promoter Holding | 90.52% | 66.69% |
| Market Cap | ₹106.86 Cr. | |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Manager fees including underwriting commission | 1.66 |
| 2 | Brokerage, selling commission and upload fees | 0.01 |
| 3 | Registrar to the Issue | 0.01 |
| 4 | Legal Advisors | 0.02 |
| 5 | Advertising and marketing expenses | 0.91 |
| 6 | Regulators including stock exchanges | 0.05 |
| 7 | Printing and distribution of issue stationary | 0.01 |
| 8 | Others, if any (market making, depositories, secretarial, peer review auditors, etc.) | 0.28 |
Last Updated on 09-Jul-2026 18:10:14